Abstract Neuromyelitis optica is an autoimmune disorder characterized by optic neuritis, transverse myelitis, and aquaporin-4 autoantibodies.
Brain Lesions May Serve as Diagnostic Criteria for Neuromyelitis Optica 2011;19(8):13. A majority of patients with neuromyelitis optica also experience disease-specific brain lesions that could help distinguish neuromyelitis optica from multiple sclerosis. MONTREAL—Imaging studies of patients with neuromyelitis optica (NMO)–spectrum disorders reveal that effects of the aquaporin-4 (AQP4) autoantibody, a marker of the disease, may extend beyond the spinal cord and optic nerve, according to researchers
MS-Related Disorders ID’d by Proteomic Pattern Analysis Last Updated: September 19, 2011. CSF proteomic pattern analysis discriminates among multiple sclerosis-related disorde Proteomic pattern analysis of cerebrospinal fluid analysis using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry distinguishes between similar multiple sclerosis-related disorders, according to a study published online Sept.
Published: October 2011 Myasthenia Gravis during the Course of Neuromyelitis Optica Masoud Etemadifar a–d , Seyed-Hossein Abtahi a–c , Alireza Dehghani a,e , Mohammad-Ali Abtahi a,e , Mojtaba Akbari a,f , Nasim Tabrizi a,d , Tannaz Goodarzi g a Medical School, Isfahan University of Medical Sciences, b Isfahan Medical Students Research Committee (IMSRC), c Isfahan Research Committee of Multiple Sclerosis, d Department of Neurology, Medical School, Isfahan University of Medical Sciences, e Ophthalmology Ward, Feiz Hospital, Isfahan University of Medical Sciences, f Department of Epidemiology and Statistics, Isfahan University of Medical Sciences, Isfahan, and g National Institute of Genetic Engineering and Biotechnology, Department of Plant Biotechnology, Canker Group, Tehran, Iran Address of Corresponding Author Case Rep Neurol 2011;3:268-273 (DOI: 10.1159/000334128) ? ? Key Words Neuromyelitis optica Devic’s syndrome Myasthenia gravis Multiple sclerosis Aquaporin-4 Interferon Thymectomy ? ? Abstract Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of the central nervous system that has been thought to be a severe subtype of multiple sclerosis for a long time. The discovery of aquaporin-4 (AQP4) antibody as a highly specific marker responsible for the pathogenesis of NMO, not only has made a revolutionary pace in establishing a serologic distinction between the two diseases, but it has also classified NMO as an antibody-mediated disorder. Similarly, myasthenia gravis (MG) is a well-known antibody-mediated disorder
A Benign Form of Neuromyelitis Optica Does It Exist? Nicolas Collongues, MD; Philippe Cabre, MD, PhD; Romain Marignier, MD; H?l?ne Z?phir, MD; Caroline Papeix, MD; Bertrand Audoin, MD, PhD; Christine Lebrun-Frenay, MD; Jean Pelletier, MD, PhD; Bertrand Fontaine, MD, PhD; Patrick Vermersch, MD, PhD; Christian Confavreux, MD, PhD; J?r?me de Seze, MD, PhD; Group Members for NOMADMUS and CF-SEP Arch Neurol. ?2011;68(7):918-924
Mayo Clinic Researcher Receives AAN’s Dystel Prize for Multiple Sclerosis Research Released: 3/31/2011 8:00 PM EDT Source: American Academy of Neurology (AAN) ? Newswise — HONOLULU – The American Academy of Neurology (AAN) is awarding the 2011 John Dystel Prize for Multiple Sclerosis Research to Brian G. Weinshenker, MD, of the Mayo Clinic in Rochester, Minnesota and a Fellow with the AAN. Weinshenker will receive the award during the AAN’s 63rd Annual Meeting in in Honolulu, held April 9 through April 16, 2011
In 1894, Eug?ne Devic (1858–1930) described a 45-year-old female hatter in whom ‘l’autopsie r?v?la l’existence d’un foyer de my?lite aigu? diffuse localis?e ? la r?gion du renflement lombaire et d’une n?vrite optique double bien marqu?e’ … the autopsy showed a focus of acute diffuse myelitis localized to the lumbar enlargement, as well as a distinct bilateral optic neuritis (Devic, 1894 ). He called the condition ‘neuromy?lite optique aig?e’
In clinical studies for the lead indication of multiple sclerosis (MS), Revimmune improves function in most patients and stops progression in over 90% of cases refractory to standard therapies.
BACKGROUND: Findings from a small clinical study suggested that statins may counteract the therapeutic effects of interferon beta (IFNbeta) in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: We conducted a post hoc analysis of data from the Safety and Efficacy of Natalizumab in Combination With IFNbeta-1a in Patients With Relapsing-Remitting Multiple Sclerosis (SENTINEL) study to determine the effects of statins on efficacy of IFNbeta. SENTINEL was a prospective trial of patients with RRMS treated with natalizumab (Tysabri, Biogen Idec, Inc., Cambridge, MA) plus IM IFNbeta-1a (Avonex, Biogen Idec, Inc.) 30 microg compared with placebo plus IM IFNbeta-1a 30 microg.
The availability of natalizumab for the treatment of multiple sclerosis has revolutionised the practice of neurology in at least one salient way: we now spend much more time thinking about progressive multifocal leukoencephalopathy (PML). The reasons for this increased attention are not difficult to identify
Multiple sclerosis is an inflammatory demyelinating disorder of the CNS. Recent studies have suggested diverse mechanisms as underlying demyelination, including a subset of lesions induced by an interaction between metabolic insult to oligodendrocytes and inflammatory mediators
OBJECTIVE: To evaluate the degree of blood-brain barrier disruption in patients with neuromyelitis optica (NMO) and to clarify whether the levels of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1) in patients with NMO can be useful biomarkers for blood-brain barrier breakdown.